Bouhanick Béatrice, Vaïsse Bernard, Schavgoulidze Anaïs, Gandia Peggy
CHU Rangueil, Fédération de cardiologie service d'hypertension artérielle et thérapeutique, TSA 50032, 1, avenue J Poulhes, 31059 Toulouse cedex 9, France; UMR 1027 université Toulouse 3, 31000 Toulouse, France.
CHU Timone, service de cardiologie, rythmologie et hypertension arterielle, 13385 Marseille, France.
Presse Med. 2019 Dec;48(12):1520-1526. doi: 10.1016/j.lpm.2019.08.009. Epub 2019 Nov 21.
Non-adherence to antihypertensive treatment is one of the critical contributors to sub-optimal blood pressure control. The French Society of Hypertension remembered that urine and serum biochemical detection of antihypertensive drugs could be useful in a patient with resistant hypertension. Talking to a patient with biochemically confirmed non-adherence to blood pressure-lowering therapy and repeating them improved adherence to drugs. Despite its usefulness, biochemical detection of antihypertensive drugs is not routinely effective in France as they are not reimbursed by French Medical Care, except in patients attending hospitals. The list of blood pressure-lowering drugs able to be biochemically detected in France and their modalities are recorded here.
不坚持抗高血压治疗是血压控制不理想的关键因素之一。法国高血压学会指出，对抗高血压药物进行尿液和血清生化检测可能有助于治疗顽固性高血压患者。与生化检测证实不坚持降压治疗的患者交谈并反复提醒他们，可提高药物依从性。尽管抗高血压药物的生化检测有用，但在法国它并非常规有效，因为除了住院患者外，法国医疗保健机构不报销此类检测费用。本文记录了在法国能够进行生化检测的降压药物清单及其检测方式。
